Investors

Press Releases

All Releases

View Summary EYLEA® (aflibercept) Injection Approved in Europe for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Aug 29, 2013
PDF 18.5 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2013 Investor Conference Presentations
Aug 27, 2013
PDF 9.3 KB Add to Briefcase
View Summary Regeneron Granted Fundamental Patents Covering Mouse Antibody Technology Used in VelocImmune® Mice
Aug 7, 2013
PDF 10.5 KB Add to Briefcase
View Summary Regeneron and Bayer Report Positive One-Year Results from Two Phase 3 Trials of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema
Aug 6, 2013
PDF 22.2 KB Add to Briefcase
View Summary Regeneron Reports Second Quarter 2013 Financial and Operating Results
Aug 6, 2013
PDF 33.6 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe
Jul 26, 2013
PDF 18.6 KB Add to Briefcase
View Summary Regeneron to Report Second Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on August 6, 2013
Jul 2, 2013
PDF 9.4 KB Add to Briefcase
View Summary Regeneron Announces First Recipients of Annual "Regeneron Prize for Creative Innovation"
Jun 27, 2013
PDF 11.3 KB Add to Briefcase
View Summary Regeneron and Bayer Report Positive Phase 3 Results for EYLEA® (aflibercept) Injection in Myopic Choroidal Neovascularization (mCNV)
Jun 6, 2013
PDF 65.3 KB Add to Briefcase
View Summary Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
May 21, 2013
PDF 20.1 KB Add to Briefcase
View Summary Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
May 15, 2013
PDF 19.9 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2013 Investor Conference Presentations
May 8, 2013
PDF 9.6 KB Add to Briefcase
View Summary Regeneron Reports First Quarter 2013 Financial and Operating Results
May 3, 2013
PDF 30.1 KB Add to Briefcase
View Summary Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs
May 3, 2013
PDF 10.8 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2013 Investor Conference Presentations
Apr 18, 2013
PDF 9.5 KB Add to Briefcase
View Summary Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013
Apr 11, 2013
PDF 9.3 KB Add to Briefcase
View Summary Regeneron Pharmaceuticals Announces Expansion in New York's Hudson Valley
Apr 4, 2013
PDF 10.5 KB Add to Briefcase
View Summary Regeneron Announces Potential Additional Royalty Stream Related to EU Approval for Ilaris® (canakinumab) in Patients Suffering Acute Gouty Arthritis Attacks Who Cannot Gain Relief From Current Treatments
Mar 4, 2013
PDF 12.3 KB Add to Briefcase
View Summary Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
Mar 2, 2013
PDF 18.2 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2013 Investor Conference Presentations
Feb 19, 2013
PDF 9.5 KB Add to Briefcase
Showing 101-120 of 282 Page: 1 2 3 4 5 6 7 8 9 10 ... 15  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase


Close
Form content here please :)